Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
1(9%)
Results Posted
71%(5 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_1
5
45%
Ph phase_2
3
27%
Ph not_applicable
2
18%

Phase Distribution

5

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
5(50.0%)
Phase 2Efficacy & side effects
3(30.0%)
N/ANon-phased studies
2(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

1

trials recruiting

Total Trials

11

all time

Status Distribution
Active(1)
Completed(7)
Terminated(2)
Other(1)

Detailed Status

Completed7
Terminated1
Withdrawn1
unknown1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
1
Success Rate
87.5%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (50.0%)
Phase 23 (30.0%)
N/A2 (20.0%)

Trials by Status

completed764%
terminated19%
withdrawn19%
unknown19%
active_not_recruiting19%

Recent Activity

1 active trials
Showing 5 of 11
completedphase_1

Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

NCT03650764
active_not_recruitingphase_2

A Study of N-acetylcysteine in Patients With COVID-19 Infection

NCT04374461
completedphase_2

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

NCT03623373
completedphase_2

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

NCT02296684
completedphase_1

BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

NCT03496662
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT03650764Phase 1

Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Completed
NCT04374461Phase 2

A Study of N-acetylcysteine in Patients With COVID-19 Infection

Active Not Recruiting
NCT03623373Phase 2

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

Completed
NCT02296684Phase 2

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

Completed
NCT03496662Phase 1

BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Completed
NCT03532217Phase 1

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Completed
NCT04133415Not Applicable

Palliative Lattice Stereotactic Body Radiotherapy (SBRT)

Completed
NCT03607955Phase 1

Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy

Withdrawn
NCT03655444Phase 1

Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy

Terminated
NCT03039101Not Applicable

Leukotriene Antagonism in Recruitment of CD49d Expressing Neutrophils in Atopic Subjects

Completed
NCT03624686

Production of Clinical-grade Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory B-cell Malignancies

Unknown

All 11 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
11